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ABSTRACT
Stroke is a leading cause of death and disability among adult population. Many pathological 
events including inflammation, oxidative stress, and apoptosis contribute to the secondary ne­
uronal death after stroke. The goal of this review is to discuss the therapeutic potential and pu­
tative mechanisms of neuroprotective properties of thiazolidinediones (peroxisome prolifera- 
tor-activated receptors-? agonists) at ischemic stroke. Thiazolidinediones have insulin-sensiti­
zing and other additional pleiotropic properties. Ischemic neuroprotection afforded by thiazo­
lidinediones has been involved anti-inflammatory, anti-oxidant, anti-apoptotic properties, as 
well as effects on endothelial function and repair. These novel actions of thiazolidinediones co­
uld offer some protection against the potentially enhanced damage of brain ischemia in pati­
ents with abdominal obesity and insulin resistance and may open new exciting lines of investi­
gation on stroke treatment.
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S troke is one of the leading causes of morbidity and mortality worldwide. In the last 2 decades, there has been an 
enormous increase in the pathophysiological 
knowledge of brain ischemia and post-ische­
mic cerebral processes.
More than 1000 neuroprotective agents 
that showed beneficial effects in pre-clinical 
studies failed in clinical trial, displayed severe 
side-effects or worsened the outcome of stro­
ke. Strategies of proven benefit for acute in­
tervention in stroke are still limited to admini­
stration of tissue plasminogen activator wit­
hin 4.5 h [24], aspirin within 48 h of stroke on­
set, stroke care unit management, and decom­
pressive surgery for supratentorial malignant 
hemispheric ischemia [45]. Thus, the dilemma 
of experimental success and practical failure 
encourages the search for new applications of 
already-approved drugs.
Brain injury after an ischemic event is an 
evolving process that can continue for days af­
ter injury. During the delayed post-ischemic
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phase, which may last for several days or even 
weeks, secondary phenomena such as inflam­
mation and apoptotic cell death may contribu­
te to further progression of brain injury [25]. 
Recently, much attention has been drawn to 
nuclear proteins - peroxisome proliferator-acti- 
vated receptors (PPARs). PPARs are ligand- 
activated transcription factors that belong to 
the nuclear hormone receptor superfamily, 
structurally similar to steroid hormone recep­
tors [15]. PPARs regulate target genes expressi­
on [9]. Most recent discoveries portray PPARs 
as promising pharmacological targets for the 
treatment of acute ischemic stroke, thanks to 
their ability to simultaneously interfere with se­
veral mechanisms that underlie the pathophysi­
ology of brain ischemia, thus leading to an in­
teresting protective strategy to counteract the 
multiple deleterious effects of ischemic and 
post-ischemic injuries [11]. Three types of 
PPARs have been identified - alpha, delta/beta 
and gamma. Each PPAR type regulates acti­
vity of definite genes and controls numerous
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processes of cellular metabolism, differentiati­
on, proliferation, apoptosis, etc. There are en­
dogenous (free fatty acids) and synthetic (fibra- 
tes, non-steroidal anti-inflammatory drugs, thi- 
azolidinediones) ligands for PPARs [5].
Thiazolidinediones (TZD), glitazones - are 
full PPAR-y agonists. TZD effects are realized 
through regulation of genes transcription invol­
ved in metabolism of fats, carbohydrates, ene­
rgy homeostasis, and activity of immune tissues 
in different organs and systems [5, 6]. TZD ha­
ve insulin-sensitizing properties in patients with 
type 2 diabetes or impaired glucose tolerance [5] 
In addition to their ability to lower insulin le­
vels, TZD increase high density lipoprotein 
cholesterol levels, decrease serum fatty acid and 
triglyceride concentrations, minimally reduce 
blood pressure, enhance fibrinolysis, improve 
endothelial cell function, decrease vascular in­
flammation, reduce oxidative stress, etc [28].
Currently, only two TZD: rosiglitazone 
and pioglitazone are approved for clinical 
practice. In the contest of cerebrovascular pa­
thology, it’s appropriate to underscore some 
features of these drugs: pioglitazone crosses 
the blood brain barrier much more easily than 
rosiglitazone [5]; however, rosiglitazone binds 
to PPAR-y with ten times more affinity than 
pioglitazone [50].
TZD are already approved for the routinely 
management of type 2 diabetes as effective in­
sulin sensitizers of peripheral tissues. However 
in recent years the breadth of indications in 
which TZD is being tested in humans has bro­
adened beyond insulin resistance, particularly 
in neurology: multiple sclerosis, extrapyrami- 
dal disorders, Alzheimer’s disease, mild cogni­
tive impairments, depressive disorders, etc. In 
relation to cerebrovascular pathology, there is 
ongoing study of the neuroprotective efficacy 
of pioglitazone (30 mg per day) in non-diabe­
tic patients in hemorrhagic stroke (Safety of 
Pioglitazone for Hematoma Resolution In In­
tracerebral Hemorrhage; see: number clinical 
trial (NCT) 00827892) and there is ongoing 
study which assesses the effects of pioglitazo-
ne, once daily on brain hemodynamics in he­
althy elderly participants (Study to Assess the 
Effects of Daily Administration of Pioglitazo­
ne on Б га т  Hemodynamics in Healthy El­
derly Participants; NCT01456117).
Recent multiple data from animal experi­
ments strongly indicate that TZD confer neuro­
protection and neurological improvement fol­
lowing cerebral ischemia. It has been performed 
meta-analysis of experimental studies in which 
TZD (either rosiglitazone or pioglitazone) were 
administered in a rodent model of focal or glo­
bal cerebral ischemia [48]. There were identified 
31 studies that investigated the use of TZD and 
a vehicle in an animal model of cerebral ische­
mia, 22 of which met the pre-specified inclusion 
criteria (measurement of mean infarct volume) 
and were further analyzed. The included studi­
es came from 19 independent research groups 
and data were analyzed from 1.348 experimen­
tal subjects for infarct volume measurements. 
10 of the studies included measurements of ne­
urological function in 939 experimental sub­
jects. In 18 of the studies, TZD was administe­
red either orally or intraperitoneally; 4 studies 
administered TZD intracerebroventricularly. 
The timing of the first dose ranged from 2 
weeks prior to ischemic insult to 1 day following 
injury. 14 studies began administration of the 
drug prior to injury, whereas 10 started treat­
ment with TZD either at the time of ischemia or 
thereafter. Rosiglitazone was administered in 
13 of the studies and pioglitazone was used in 
the remaining 9 studies.
TZD treatment significantly reduced in­
farcts sizes by 54% (effect size (ES) 1.54; confi­
dence interval (CI) 1.40-1.68; p<0,00001) and 
improved neurological outcome by 19% (ES 
1.19; CI 1.04-1.34; p<0.00001) in comparison 
with vehicle-treated controls. Rosiglitazone 
and pioglitazone were analyzed separately for 
their effects on infarct volume and neurolog­
ical deficits. Rosiglitazone decreased lesion vo­
lume by 55% (ES 1.55; CI 1.39-1.72; 
p<0.00001) and improved neurological outco­
me by 19% (ES 1.19; CI 0.99-1.38; p<0.00001).
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Pioglitazone also reduced lesion size by 50% 
(ES 1.50; CI 1.24-1.76; p<0.00001) and impro­
ved neurological outcome by 20% (ES 1.2; CI 
0.95-1.44; p<0.00001). There was no difference 
in the effectiveness of the two different drugs 
with regard to either infarct volume (p=0.73) 
or neurological deficits (p=0.95).
TZD treatment was effective at reducing le­
sion volume and improving neurological outc­
omes when dosed prior to or after the inducti­
on of focal or global ischemia. When dosed be­
fore ischemic injury, TZD decreased infarct si­
ze by 56% (ES 1.56; CI 1.36-1.76; p<0.00001) 
and improved neurological outcomes by 12% 
(ES 1.12; CI 0.96-1.29; p<0.00001). Adminis­
tering TZD at or after the induction of ische­
mic stroke also reduced lesion volume by 52% 
(ES 1.52; CI 1.32-1.72; p<0.00001) and impro­
ved neurological outcomes by 73% (ES 1.73; 
CI 1.26-2.19; p<0.00001). There was no diffe­
rence in lesion volume reduction because of 
dose timing (p=0.78). Treatment with TZD af­
ter the onset of ischemic injury resulted in a 
greater improvement in neurological outcomes 
than did dosing prior to ischemia (p=0.02). 
The effects of rosiglitazone on the reduction of 
lesion size were similar whether it was admini­
stered before or after ischemia (p=0.25). Piog- 
litazone was more effective at reducing lesion 
volume when administered before the inducti­
on of ischemia (p=0.01). These findings may 
support the idea that TZD have an extended 
therapeutic window for the treatment of ische­
mic stroke, as it targets delayed pathways.
The effects of TZD on anatomic and neuro­
logical outcomes significantly differed based on 
the route of drug administration. Dosing TZD 
by food-based administration tended to be less 
effective at reducing infarct volume than intra- 
peritoneal (p<0.05), intracerebroventricular 
(p<0.05). Conversely, for neurologic outcome, 
the efficacy according to route of administrati­
on was highest with peroral, followed by intra- 
peritoneal and intracerebroventricular delivery 
(p<0.05 between all groups) [48].
This ischemic neuroprotection afforded by
TZD has been involved anti-inflammatory, an­
ti-oxidant, anti-apoptotic properties, as well as 
effects on endothelial function and repair [15].
Post-ischemic cerebral inflammation is es­
sential for necrotic core clearing and formation 
of gliosis following ischemia [33]. The timing 
and the level of activation of different inflam­
matory components define the beneficial ver­
sus the damaging effects of local cerebral in­
flammation [4]. The increased post-ischemic 
expression of adhesion molecules and selectins 
on blood vasculature mediates leukocyte-endo­
thelial cell interactions followed by blood brain 
barrier breakdown and leukocyte infiltration 
into the brain parenchyma [18, 43]. The infil­
trated macrophages and neutrophils activate 
resident microglia and astrocytes [18]. Follo­
wing stroke, leukocytes as well as neurons, ast­
rocytes, microglia, and oligodendrocytes gene­
rate proinflammatory mediators (cytokines, 
chemokines, and prostaglandins), free radicals, 
other neurotoxic substances which exacerbate 
post-ischemic secondary neuronal death [1, 26].
In experiment pre-treatment as well as post­
treatment with rosiglitazone significantly 
decreased the post-ischemic intercellular adhe­
sion molecule-1 expression and extravasation 
of macrophages and neutrophils into brain. 
Moreover, rosiglitazone treatment curtailed 
the post-ischemic expression of the pro-inflam­
m atory genes interleukin-1?, interleukin-6, 
macrophage inflammatory protein-1?, m o­
nocyte chemoattractant protein-1, cyclooxyge- 
nase-2, inducible nitric oxide synthase, early 
growth response-1, nuclear factor-kappa Б in 
ischemic hemispheres. Rosiglitazone also incre­
ased the expression of the anti-inflammatory 
gene suppressor of cytokine signaling-3 and 
prevented the phosphorylation of the trans­
cription factor signal transducer and activator 
of transcription-3 after focal ischemia [46].
Neutrophils are the earliest leukocyte sub­
type to show substantial up-regulation in gene 
expression and to infiltrate areas of cerebral 
ischemia [12]. Compared to the control group, 
the administration of rosiglitazone, starting
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24 h after focal cerebral ischemia prevented 
neutrophilia in blood (p<0.005) 72 h after me­
dial cerebral artery occlusion/reperfusion [2].
In response to ischemic injury, TZD decre­
ase cyclooxygenase-2 expression, reduce the 
secretion of proinflammatory mediators and 
neurotoxic molecules (interleukin-1?, interleu­
kin-6, tumor necrosis factor-?, matrix metallo- 
proteinase-9, myeloperoxidase, inducible nit­
ric oxide synthase) in peri-infarct brain areas 
[7, 31, 34, 44, 51].
TZD affect the generation of radical oxyg­
en species on various levels. These drugs in­
duce the expression of the anti-oxidant enzy­
mes copper/zinc-superoxide dismutase and ca- 
talase in affected hemispheres [42, 46]. The tre­
atment of rats with either pioglitazone or rosi- 
glitazone before focal cerebral ischemia decre­
ased the production of radical oxygen species 
and nitrite, decreased lipid peroxidation and 
reversed the depleted stores of glutathione [16]. 
TZD attenuate the expression of inducible nit­
ric oxide synthase in inflammatory cells [44], 
which is considered to be an important source 
of the deleterious radical peroxynitrite.
Prevention of apoptosis is one of major 
mechanisms thought to underlie TZD neuro­
protection after ischemic brain injury [20, 21]. 
Apoptosis may be responsible for up to 50% 
of cellular deaths after cerebral ischemia [22]. 
Rosiglitazone treatment resulted in decreased 
apoptosis, measured as reduction of caspase-3 
activity in the ischemic cortex in a rat infarcti­
on model [32]. Delayed rosiglitazone therapy 
(24 h after cerebral ischemia) significantly pre­
vented DNA fragmentation in the cortical 
area adjacent to the necrotic core, indicating 
that the relative risk of apoptosis in the cont­
rol group was more than 8 times higher than 
in rosiglitazone treated animals [2].
In experimental ischemic strokes it has be­
en demonstrated that rosiglitazone-fed rats 
showed the increased endothelial nitric oxide 
synthase expression in vessels of ischemic he­
mispheres and enhanced angiogenesis around 
the ischemic margin [13].
So far, there are limited clinical data on 
TZD use in patients with ischemic strokes.
The use of pioglitazone, as a preventive ap­
proach to ischemic brain injury has been 
recently addressed by two large clinical trials: 
the Prospective Pioglitazone Clinical Trial in 
Macrovascular Events (PROactive) and the 
Insulin Resistance Intervention after Stroke 
(IRIS). The PROactive trial randomized 5238 
patients with type II diabetes and a history of 
macrovascular disease to the pioglitazone (15­
45 mg per day) or placebo. The average time of 
observation was 34.5 months. The PROactive 
study has demonstrated that pioglitazone sig­
nificantly reduces the combined risk of heart 
attacks, strokes and death by 16% in high risk 
patients with type 2 diabetes (hazard ratio 
(HR) 0.84; 95% CI, 0.72-0.98; p<0.03) [19]. 
Moreover, in a subgroup analysis of PROacti­
ve study, pioglitazone reduced the risk of a re­
current stroke by 47% (HR 0.53; 95% CI, 0.34­
0.85; r=0.0085) [49]. However, it remains 
unclear whether the suggested beneficial ef­
fects of pioglitazone secondary stroke preven­
tion are mediated by insulin sensitization or by 
additional observed reductions in risk factors, 
such as arterial hypertension and dyslipide- 
mia. This question and that related to the po­
tential beneficial effects of pioglitazone in non­
diabetic patients with stroke will be addressed 
by the IRIS trial (NCT00091949), a randomi­
zed trial on more than 3000 non-diabetic sub­
jects who are insulin resistant and have had a 
recent transient ischemic attack or ischemic 
stroke. The IRIS study began on February 
2005 and it is still recruiting patients.
In the Carotid Intima-Media Thickness in 
Atherosclerosis Using Pioglitazone (CHICA­
GO) trial, which involved 462 patients with 
type 2 diabetes (most of whom had no history 
of cardiovascular disease), pioglitazone 15-45 
mg/day (over 18 months) significantly slowed 
the progression of carotid intima-media 
thickness, a validated measure of atheroscle­
rosis progression [36].
Researches from Yale University School of
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Medicine had determined the effectiveness of 
pioglitazone (45 mg per day) compared with 
placebo for improving insulin sensitivity amo­
ng non-diabetic patients with a recent transi­
ent ischemic attack or non-disabling ischemic 
stroke and impaired insulin sensitivity. Pati­
ents assigned to pioglitazone (n=10) and 
placebo (n=10) were similar in insulin sensiti­
vity, age and obesity. The mean proportional 
increase in insulin sensitivity was 62% among 
patients assigned to pioglitazone compared 
with a 1% decline among patients assigned to 
placebo (p<0.001). Thus, pioglitazone is ef­
fective for improving insulin sensitivity amo­
ng patients with recent ischemic episodes and 
impaired insulin sensitivity [29].
In a controlled study 30 stroke patients with 
type II diabetes, admitted for acute inpatient 
stroke rehabilitation, receiving pioglitazone or 
rosiglitazone were matched for age, sex, functi­
onal disability and interval post-stroke with 30 
stroke patients with type II diabetes not recei­
ving TZD. Use of TZD was associated with 
enhanced functional recovery (p=0.015) [30].
Interestingly, high plasma levels of 15-delta- 
prostaglandin J2 (endogenous PPAR-? agonist, 
which share neuroprotective effects of TZD in 
experimental models of ischemic stroke [38]) 
have been associated with good neurological 
outcome and smaller infarct volume in patients 
with an acute atherothrombotic stroke [8].
Thus, TZD may be associated with benefici­
al effects after cerebral ischemia in patients with 
insulin resistance. On the other hand, it is well 
known, abdominal obesity in most cases is as­
sociated with insulin resistance and lipotoxicity.
Most of the research about the obesity and 
cerebrovascular disease has been restricted to 
the field of stroke prevention. However, some 
of the metabolic abnormalities and risk 
factors that integrate the lipotoxicity have be­
en associated with a worsening of stroke outc­
omes. In this context, obesity-related alterati­
ons, as components of metabolic syndrome, 
comprise impairment in the endogenous fibri­
nolytic capacity, hyperglycemia, endothelial
dysfunction, chronic endothelial damage, and 
a proinflammatory state, all of which may 
contribute to amplify cerebral ischemic dama­
ge and to hamper arterial recanalization [3].
Recently it has been found that obesity incre­
ases severity of strokes and may determine the 
clinical course of diseases. Elevated body mass 
index is associated with a lower likelihood of be­
ing discharged home and a trend toward exten­
ded hospital stay among patients hospitalized 
for ischemic stroke [39]. Functional state (accor­
ding to Бarthel index) of the subjects with obes­
ity/overweight at discharge from hospital after 
ischemic strokes was actually worse in compari­
son to the subject with the normal weight [40]. 
We have identified that abdominally obese pati­
ents with cerebral infarction volumes more than 
20 cm3 (according to MRI investigation), have 
more severe clinical course of ischemic strokes 
according to NIHS scale, slower regression of 
neurological symptoms and worse functional 
outcomes according to modified Rankin scale in 
comparison with normal weight patients [52].
TZD decrease the expression of lipotoxic 
adipokines and increase the level of circulati­
ng adiponectin [10, 47]. For example, Japane­
se researches examined short-term effects of 
pioglitazone (30 mg per day) on serum adipo- 
nectin in non-diabetic subjects with normal 
glucose tolerance. Adiponectin level rapidly 
and reliably (p<0.05) increased within 3 days 
of pioglitazone treatment in all subjects and 
continued to increase throughout the study; 
moreover, decrease in leptin levels were de­
tected after 14 days, but it was not statistically 
significant [27]. In the double-blind, randomi­
zed, controlled trial it has been determined the 
effects of pioglitazone (30-45 mg per day for 
duration of 6 months) in healthy, abdominally 
obese men and women. Serum adiponectin le­
vels rose sharply (p<0.001) in the treatment 
groups. A significant positive correlation was 
observed between the change of the adipo- 
nectin levels and subcutaneous fat [41].
Which adverse side-effects of TZD must be 
taken into consideration? These drugs cause an
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increase in body weight, hemodilution, perip­
heral edema, and deterioration of cardiomyo­
pathies. Pioglitazone can produce slight weight 
gain, in some studies average of 3 kg. [14]. 
However, it has been found that TZD redistri­
bute of fat in favor of subcutaneous fraction by 
reducing the amount of visceral fraction [17]. 
As is known, just visceral fat is associated with 
insulin resistance and lipotoxicity.
Fluid retention manifests as peripheral ede­
ma occurs in 4% to 6% of patients treated with 
TZD. Peripheral edema may worsen existing 
heart failure or cause new onset heart failure. 
However, randomized controlled trials have 
clearly shown increased rates of hospitalizati­
on for heart failure due to TZD, but not incre­
ased mortality [35].
Rosiglitazone is thought to be related to 
bone fractures in postmenopausal women by 
suppressing osteoblastogenesis (bone formati­
on) and stimulating osteoclastogenesis (bone 
resorption) [23].
One meta-analysis of 42 randomized trials 
involving 27.000 patients demonstrated that 
rosiglitazone is associated with the increase in 
the risk of myocardial infarction by 43% (HR
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РЕЗЮМЕ
ТИАЗОЛИДИНДИОНЫ И ИШЕМИЧЕСКИЙ ИНСУЛЬТ 
Литвиненко Н.В., Дельва М.Ю.
Кафедра нервных болезней с нейрохирургией и медицинской генетикой 
Украинская медицинская стоматологическая академия, Полтава, Украина
Инсульт является одной из ведущих причин смертности и инвалидности среди взросло­
го населения. Обзор литературы посвящен анализу экспериментальных и клинических 
данных о влиянии тиазолидиндионов (лекарственных препаратов - агонистов гамма-ре - 
цепторов, активирующих пролиферацию пероксисом) на развитие и течение ишемичес­
ких инсультов. Тиазолидиндионы рутинно применяются в лечении сахарного диабета, 
как сенситизаторы периферических тканей к инсулину. Кроме того, тиазолидиндионы 
обладают дополнительными плейотропными свойствами. Современные научные иссле­
дования доказывают наличие противовоспалительных, антиоксидантных и антиапоп- 
тозных эффектов у тиазолидиндионов при постишемических церебральных поражениях. 
Терапия тиазолидиндионами может рассматриваться как потенциальное средство пато­
генетического лечения постишемических церебральных нарушений у пациентов с абдо­
минальным ожирением и инсулинорезистентностью. Однако, для окончательного выяс­
нения краткосрочных и долгосрочных эффектов тиазолидиндионов при ишемических 
инсультах необходимо проведение рандомизированных исследований.
Ключевые слова: ишемический инсульт, патогенез, тиазолидиндионы, нейропротекция.
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XULAS0
TiAZOLiDiNDiONLAR У 0 І§ЕМІК iNSULT 
Litvinenko N.B., Delva M.Yu.
Neyrocdrrahiyyd vd tibbi genetika ild birgd sinir xdstdlikldri kafedrasi 
Ukrayna tibbi stomatoloji akademiya, Poltava, Ukrayna
Insult ya§li shali arasinda olUm vs slilliyin aparici ssbsblsrindsn biridir. Odsbiyyat icmali tia- 
zolidindionlarin (peroksisomun proliferasiyasini aktivls§dirsn qamma reseptorlarin aqonistls- 
ri) i§emik insultlarin inki§afi vs gedi§ins tssiri haqda eksperimental vs kliniki mslumatlarin 
analizins hssr edilib. Tiazolidindionlar §sksrli diabetin mUalicssinds periferik toxumalarin in­
sulins qar§i hsssasligini artirmaq U^Un rutin olaraq istifads olunur. Бundan ba§qa tiazolidindi­
onlar slavs olaraq pleyotrop xUsusiyystlsrs malikdir. MUasir elmi tsdqiqatlar tiazolidindionla- 
rin posti§emik serebral zsdslsnmslsr zamani iltihabsleyhi, antioksidant vs antiapoptoz effekt- 
lsrs malik olmasini sUbut edir. Tiazolidindionlar abdominal piylsnms vs insulins qar§i rezisten- 
tliyi olan xsstslsrds posti§emik serebral zsdslsnmslsrin patogenetik mUalicssi U^un potensial 
vasits ola bilsr. Amma tiazolidindionlarin i§emik insultlar zamani tez vs gecikmi§ effektlsrini 
tam oyrsnmsk U^un, randomizsolunmu§ tsdqiqatlarin aparilmasi vacibdir.
A?ar sozlar: i§emik insult, patogenez, tiazolidindionlar, neyroproteksiya.
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